Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yankening is a traditional Chinese medicine (TCM) oral formulation developed and manufactured by Guangdong Xinbao Pharmaceutical. It is primarily used for its heat-clearing, detoxifying, and anti-inflammatory properties. The medication is typically composed of five herbal ingredients: *Phellodendri Chinensis Cortex* (Huangbai), *Rhei Radix et Rhizoma* (Dahuang), *Coptidis Rhizoma* (Huanglian), *Scutellariae Radix* (Huangqin), and *Isatidis Radix* (Banlangen). These components contain active alkaloids and flavonoids, such as berberine and baicalin, which contribute to its therapeutic effects against acute tonsillitis, pharyngitis, and gastritis. It is an approved pharmaceutical product in China, most commonly found in tablet form (Yankening Pian).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yankening.